Repligen (NASDAQ: RGEN) reported Q1 EPS of $0.28, $0.02 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $151.3 million versus the consensus estimate of $150.06 million.

GUIDANCE:

Repligen sees FY2024 EPS of $1.42-$1.49, versus the consensus of $1.46. Repligen sees FY2024 revenue of $620-650 million, versus the consensus of $637.8 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.